NETRI

Better science, better medicines — and a clearer path for NAM adoption. A recent Inside EMA interview with Stefano Ponzano, Head of European Medicines Agency’s Office of Translational Sciences, highlights several principles that are becoming increasingly important for the regulatory adoption of New Approach Methodologies. The objective is not to eliminate animal testing overnight. It is to build a progressive transition toward more human-relevant and predictive methodologies, while maintaining the level of evidence required to protect patient safety. Several key messages stand out: 🔹 NAMs should be considered as part of a weight-of-evidence approach, combining advanced in vitro models, Organ-on-Chip technologies, computational modelling, AI and, when still scientifically justified, targeted animal studies. 🔹 Organ-on-Chip technologies are explicitly recognised as an important component of the NAM ecosystem. 🔹 The objective is not necessarily to reproduce an existing animal test one-to-one, but to demonstrate that a methodology can reliably address a clearly defined regulatory question and context of use. 🔹 Early interaction with regulators is becoming essential. The European Medicines Agency is encouraging dialogue with technology developers before methodologies are incorporated into formal regulatory submissions, helping align evidence generation with regulatory expectations. 🔹 Finally, international regulatory convergence will be critical, with collaboration across European Medicines Agency, FDA, Pharmaceuticals and Medical Devices Agency, Health Canada | Santé Canada, Therapeutic Goods Administration, Swissmedic and other agencies. For NETRI, these principles reinforce a core approach to NAM development: Start from the context of use. Define the decision that needs to be supported. Generate the right biological and functional evidence. The future of Organ-on-Chip and MPS technologies will not depend only on increasingly sophisticated models. It will depend on their ability to generate reproducible, decision-relevant and regulatory-actionable data. This is where advanced human biology, engineering, data science and regulatory science need to converge. ▶️ Watch the full Inside EMA interview: https://lnkd.in/eGzU2qMX

From validation to implementation: NAMs are entering a new era. On July 21, NETRI joined France Biotech, Ipsen and Servier for a webinar dedicated to the impact of regulatory evolution on the use of animals for scientific purposes. Benoît Maisonneuve - PhD, Director Strategic Partnerships & Regulatory Affairs at NETRI, provided an overview of the rapidly evolving NAMs regulatory landscape across the US, Europe, the UK and Asia, while Thibault Honegger, CEO & Co-founder of NETRI, joined the industry roundtable on the concrete integration of NAMs into drug development. One major conclusion emerged: The question is no longer only whether a NAM works. The question is: for which decision can we trust it? Across regions, regulatory pathways differ. But a common scientific framework is progressively emerging: Context of Use → Human Biological & Mechanistic Relevance → Technical Characterization → Fit-for-Purpose → Regulatory Confidence For NETRI, this evolution reinforces a core conviction: the value of human-relevant models is not simply to reproduce biology or replace an animal model one-to-one. It is to generate actionable human data early enough to improve drug-development decisions. This is also the rationale behind NETRI's work in chemotherapy-induced peripheral neuropathy (CIPN), where the company is progressively building the evidence required to move from a scientifically relevant model toward a clearly defined regulatory use case. The next phase for NAMs will require more than technology. It will require standardization, reproducibility, industrial deployment, regulatory dialogue and evidence generated around clearly defined Contexts of Use. Thank you to France Biotech, Catherine George, Dorinne Desposito, Jean Philippe Stephan and all participants for this important discussion.

🧠 Today is World Brain Day. This year’s theme, “Brain Health: Access for All,” is a reminder that progress in brain health depends not only on better care, but also on our ability to better understand neurological diseases and develop more effective therapies. At NETRI, this starts before the clinic. Our models of neurodegenerative disease are designed to reproduce key mechanisms involved in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and ALS, providing new tools to investigate disease progression, evaluate therapeutic candidates and generate functional neuronal readouts. From studying synaptic dysfunction and neuronal network alterations to discriminating the biological effects of CSF from Alzheimer’s patients, our objective is to make neuronal function a measurable and actionable component of preclinical drug development. Because developing better treatments for brain disorders requires better models of the human brain. On #WorldBrainDay, NETRI remains committed to advancing more predictive, human-relevant approaches to neurological research and helping translate neuroscience into better therapeutic decisions. https://lnkd.in/ev3PyDDV

NETRI is proud to be recognized by Amgen as the winner of the 2026 Amgen x NSG BioLabs Golden Ticket in Singapore. This award represents an important milestone in NETRI’s international development and a strong recognition of its scientific approach to advancing more predictive, human-relevant drug development. Through its Neuron-as-a-Sensor technology, NETRI aims to generate decision-grade insights for preclinical safety and drug discovery by leveraging human neurons as functional biological sensors. The opportunity to establish a presence at NSG BioLabs and engage with Amgen’s scientific and business ecosystem will support the next phase of NETRI’s development, with a focus on strengthening the robustness, transferability and regulatory readiness of its platform. NETRI sincerely thanks Amgen and NSG BioLabs for their trust and looks forward to contributing to Singapore’s dynamic biotech ecosystem while building new scientific and strategic partnerships across the region. Alan Russell, Hasyim Sim, Jolene Ooi Thibault Honegger Sebastien Mosser Laura Ejarque

📢 WEBINAIRE | Impact de l’évolution de la réglementation sur l’utilisation des animaux à des fins scientifiques Demain, mardi 21 juillet de 12h30 à 14h, retrouvez Thibault Honegger, PDG et Co-fondateur de NETRI, ainsi que Benoît Maisonneuve - PhD, Directeur des Partenariats Stratégiques et des Affaires Réglementaires, à l’occasion du webinaire organisé par France Biotech : 👉 « Impact de l’évolution de la réglementation sur l’utilisation des animaux à des fins scientifiques » Aux côtés d’experts du secteur, ils reviendront notamment sur les évolutions réglementaires en cours, la place croissante des New Approach Methodologies (NAMs) et leur impact sur la recherche biomédicale et le développement de médicaments. Cette discussion intervient également dans un contexte particulièrement dynamique pour l’écosystème français, avec le lancement récent de l’appel à projets France 2030 consacré à la démonstration de la valeur des organoïdes et organes sur puce, opéré par Bpifrance. L’occasion également d’échanger sur le développement de la filière française des organoïdes et organes sur puce avec Thibault Honegger, copilote de la filière française F3OCI - Filière Française des Organoïdes et Organes-sur-puce. 📅 Mardi 21 juillet 2026 ⏰ 12h30 – 14h 💻 En ligne 🔗 Inscription : https://lnkd.in/ebittV7i Merci à France Biotech pour l’organisation de cet échange à un moment clé pour l’adoption de nouvelles approches plus prédictives et pertinentes pour l’humain. 🎤 Avec également les interventions de : • Dorinne Desposito, Predictive Toxicology Project Manager, Ipsen • Jean Philippe Stephan, Senior Director Research Pharmacology & Global Central Lab, Servier • Catherine George, Membre du CA France Biotech & Chair REED Scientific Committee, Ipsen

📢 NETRI WINS 2026 Amgen X NSG BioLabs GOLDEN TICKET FOR ITS PROPRIETARY HUMAN NEURONS-AS-A-SENSOR NEUROFLUIDICS PLATFORM. “We are honoured to receive the Amgen x NSG BioLabs Golden Ticket,” said Thibault Honegger, CEO and Co-founder of NETRI, describing the award as “an important step in the international deployment of NETRI’s Neuron-as-a-Sensor technology.” Our goal is to use human neurons as functional biological sensors to generate decision-grade insights for preclinical safety and drug discovery, helping pharmaceutical teams better predict safety and efficacy before clinical trials. “NETRI stood out for its innovative approach to addressing a significant challenge in drug development and for the strength of its scientific vision,” said Dr Alan Russell, Vice President, Large Molecule Discovery, and Head, R&D Technology & Innovation at Amgen. “The company reflects the kind of thinking that can help advance how new medicines are developed and evaluated. At Amgen, we believe great science reaches its full potential when it can be translated into meaningful patient impact.” As this year’s recipient, NETRI will receive a one-year residency at NSG BioLabs, including access to certified BSL-2 laboratory facilities, as well as networking opportunities through Amgen’s ecosystem of scientific and business leaders. Singapore offers a highly strategic environment for this next phase, combining world-class biotech infrastructure, access to dynamic cell biology capabilities, strong AI-driven drug discovery ecosystems and proximity to regional partners. Through NSG BioLabs and the opportunity to engage with Amgen’s scientific and business teams, we aim to strengthen the robustness, transferability and regulatory readiness of our platform, supporting the broader adoption of New Approach Methodologies (NAMs) in drug development. News Release on Amgen Singapore website here 👉 https://lnkd.in/eE7s-byd News Release on NETRI website here 👉 https://lnkd.in/eUpZv5t7 Alan Russell, Hasyim Sim, Jolene Ooi Thibault Honegger Sebastien Mosser Laura Ejarque

🇯🇵 Intense first day in Japan for our CEO & Co-founder Thibault Honegger with JETRO - Japan External Trade Organization. Thibault Honegger is in Osaka, Japan, this week as part of a business mission organized with JETRO - Japan External Trade Organization , with a first day already full of high-quality meetings and strategic discussions. The agenda included exchanges with the @Osaka International Cancer Institute, participation in @HealthX Connect Osaka, and presence at the @Japanese Society of Toxicology alongside our Japanese distributor HIGUCHI INC. and Shinya Watanabe , together with Lyonbiopôle Auvergne-Rhône-Alpes and Erick Lelouche, strengthening bridges between the French and Japanese health innovation ecosystems. These discussions reinforce one strong conviction: NAMs, organs-on-chip and functional approaches such as those developed by NETRI are gaining strong momentum in Japan, especially when they address concrete challenges in predictivity, toxicology, and reducing uncertainty in pharmaceutical development using our Neuron as a sensor technology. A warm thank you to JETRO - Japan External Trade Organization, HIGUCHI INC., Lyonbiopôle Auvergne-Rhône-Alpes, Axion BioSystems and all the partners we met for the quality of the exchanges and the outstanding welcome. And a small highlight of the day from our CEO & Co-founder Thibault Honegger: apparently, even the carpets in Japan had anticipated our arrival… we clearly spotted a little NETRI-logo inspiration there !

Many thanks Hitoshi Naraoka, Ph.D, MBA indeed shaping an one of unique kind international collaboration across industrial partners for NAMs IAMPS and Japan.

Wrapping up an intense and energizing week at BIO International in San Diego for our CEO & Co-founder Thibault Honegger. A week filled with strategic discussions with pharma, biotech, investors, translational science leaders, and NAMs stakeholders — all converging around the same question: how can we make preclinical decision-making more human-relevant, more predictive, and more actionable? For NETRI, this week was a strong confirmation that the momentum around Neuron-as-a-Sensor technologies, organ-on-chip systems, functional electrophysiology, and AI-powered biological signatures is accelerating. From safety to efficacy, from pain and neurotoxicity to dermatology, inflammation, neuromuscular models and broader NAMs applications, the need for robust human-relevant platforms is becoming increasingly clear. More then 30 high level meetings on NETRI’s NaaS platform, our Digital Signature strategy, and the industrialization of functional NAMs for pharma decision-making. Our CEO and co-founder Thibault Honegger is now back in Lyon, but not for long... Starting Monday, he'll be heading back to Japan with JETRO - Japan External Trade Organization to attend the XX and XX, as well as the @Japan Society Of Toxicology with our distributor HIGUCHI INC. 

🚀 NETRI joins Dassault Systèmes’ 3DEXPERIENCE Lab program to accelerate its industrialization. This collaboration marks a major step in NETRI’s trajectory: bringing NAMs technologies and predictive biological models to an industrial scale, with the robustness, traceability, and reproducibility required by the pharmaceutical, chemical, and cosmetic industries. Through the integration of the 3DEXPERIENCE Lab platform, NETRI will further digitalize its production chain and biological platform, with several key objectives: 🔹 standardizing manufacturing processes 🔹 strengthening traceability across operations and design iterations 🔹 improving device reproducibility and quality 🔹 optimizing the management of biological experiments 🔹 preparing scalable production aligned with Industry 4.0 standards This milestone is essential to support the industrial deployment of our Neurons as a Sensor approach, which uses human neural networks as functional biological sensors to generate predictive digital signatures of compound efficacy and safety. At NETRI, we believe the future of preclinical models lies at the convergence of human biology, engineering, data, and digitalized industrial systems. By joining forces with Dassault Systèmes, we are structuring this ambition with a clear objective: making biological models more reliable, more reproducible, and easier to deploy at scale. 👉 Read the full article: https://lnkd.in/e2bikX3e